Human Insulin Market Trends and 2025 Forecast
The Latest Comprehensive
Industry research study titled, “Human Insulin Market by Products, Application - Global Industry
Analysis and Forecast To 2025” published by Crystal Market Research.
Diabetes is a chronic disease which occurs either when the
pancreas fails to develop sufficient insulin or when the human body is unable
to effectively use the insulin. Symptoms associated with diabetes are frequent
urination, blurred vision, increased thirst, rapid weight loss, numbness or
tingling sensation in hands or feet and increased hunger. Factors which
increase the risk of diabetes are ethnicity, family history, unhealthy diet,
physical inactivity and smoking. Diabetes can damage the heart, eyes, blood
vessels, kidneys, and nerves which may lead to disability and premature death.
There are three types of diabetes, namely, type 1, type 2 and gestational
diabetes. Type 1 diabetes can cause due to complex interaction between genes
and environmental factors. The most common risk factors for type 2 diabetes are
overweight and obesity. However, gestational diabetes develops only during
pregnancy.
Human Insulin
is created in laboratory by growing insulin proteins within E-coli bacteria.
Human insulin regulates the blood glucose levels. The long acting insulin stays
in the body for up to 24 hours, whereas the intermediate acting insulin stays
in the body for 16 to 24 hours. Another form of insulin is short acting insulin
which stays in the body for 6 to 8 hours. The next form of insulin is rapid
acting insulin which stays in the body for 3 to 5 hours. Further, premixed
analog insulin is also a form of insulin which is used in diabetes. It is made
by combining rapid acting and long acting insulin. Absorption of the insulin
can be delayed due to smoking and scarring. Human insulin is absorbed more
rapidly as compared to insulin and it causes lesser autoimmune diseases.
The
major factor driving the human insulin market is the increasing prevalence of
diabetes. According to International Diabetes Federation, in 2015, diabetes
affected 415 million people worldwide and this number is expected to reach up
to 642 million by 2040. Moreover, increase in the prevalence of obesity will
also fuel the growth of this market. For instance, as per WHO, in 2014, more
than 1.9 billion adults, 18 years and older, were overweight, and out of these,
over 600 million were obese. Moreover, it states that, in 2014, 41 million
children whose age was under 5 were obese or overweight. However, strict
regulatory requirements for the approval of human insulin product will hamper
the growth of human insulin market.
The key
strategy adopted by the major players in the market is product launch to gain
more share. For instance, in November 2016, Novo Nordisk A/S received FDA
approval for Xultophy which is a combination of Tresiba and Victoza. By the
launch of Xultophy, Novo Nordisk A/S will gain more market share.
Major Market Players:
Ø
Novo
Nordisk A/S
Ø
Biocon
Ø
Sanofi
Ø
SemBioSys
Ø
Julphar
Ø
Wockhardt
Limited
Ø Eli Lilly and Company.
Human Insulin Market Segmentation:
By Type:
- Modern Human Insulin
o Rapid Acting
o Long Acting
o Premixed Modern
- Traditional Human
Insulin
o Short Acting
o Intermediate Acting
o Premixed Traditional
By Brand:
- Modern Human Insulin Brands
o Apidra
o Humalog
o Levemir
o NovoRapid
o NovoMix
o Lantus
By
Region:
- North America
o U.S
o Canada
o Mexico
- Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
- Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
- Rest of the World
o Brazil
o South Africa
o Saudi Arabia
o Turkey
o United Arab Emirates
o Others
About Us:
Crystal
Market Research is a U.S. based market research and business intelligence
company. Crystal offers one stop solution for market research, business
intelligence, and consulting services to help clients make more informed
decisions. It provides both syndicated as well as customized research studies
for its customers spread across the globe. The company offers market
intelligence reports across a broad range of industries including healthcare,
chemicals & materials, technology, automotive, and energy.
Contact Us:
Judy
304 South Jones Blvd, Suite 1896,
Las Vegas NV 89107,
United States
Toll Free: +1-888-213-4282
304 South Jones Blvd, Suite 1896,
Las Vegas NV 89107,
United States
Toll Free: +1-888-213-4282
Comments
Post a Comment